Chronic administration of the soluble, nonbacterial fraction of kefir attenuates lipid deposition in LDLr−/− mice

Nutrition

Volumn 35, Issue , 2017, Pages 100-105

  Santanna, Adriélly F ^a   Filete, Placielle F ^a   Lima, Ewelyne M ^a   Porto, Marcella L ^b,c   Meyrelles, Silvana S ^b   Vasquez, Elisardo C ^a,b   Endringer, Denise C ^b   Lenz, Dominik ^b   Abdalla, Dulcineia S P ^d   Pereira, Thiago M C ^a,c   Andrade, Tadeu U ^a  

^a UNIVERSIDADE VILA VELHA   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c Federal Institute of Education   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Cytokines; Kefir; LDLr ; Probiotics

Indexed keywords

CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; KEFIR; LOW DENSITY LIPOPROTEIN RECEPTOR; TUMOR NECROSIS FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; HYPERCHOLESTEROLEMIA; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 6 BLOOD LEVEL; LIPID ANALYSIS; LIPID DIET; LIPID STORAGE; MALE; MILK; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; TREATMENT RESPONSE; ANIMAL; ATHEROSCLEROSIS; BLOOD; DIET THERAPY; GENETICS; LIPID METABOLISM; METABOLISM; MICROBIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET, HIGH-FAT; HYPERCHOLESTEROLEMIA; INTERLEUKIN-10; INTERLEUKIN-6; KEFIR; LIPID METABOLISM; MALE; MICE; MICE, TRANSGENIC; RECEPTORS, LDL; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85013770202     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2016.11.001     Document Type: Article

References (54)

1. [1] Galkina, E., Ley, K., Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27 (2009), 165–197.
2. [2] Vasquez, E.C., Peotta, V.A., Gava, A.L., Pereira, T.M., Meyrelles, S.S., Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci, 19, 2012, 22.
3. [3] Leal, M.A., Balarini, C.M., Dias, A.T., Porto, M.L., Gava, A.L., Pereira, T.M., et al. Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: The beneficial effects of sildenafil. Curr Pharm Biotechnol 16 (2015), 517–530.
4. [4] Lusis, A.J., Atherosclerosis. Nature 407 (2000), 233–241.
5. [5] Pereira, T.M., Nogueira, B.V., Lima, L.C., Porto, M.L., Arruda, J.A., Vasquez, E.C., et al. Cardiac and vascular changes in elderly atherosclerotic mice: the influence of gender. Lipids Health Dis, 9, 2010, 87.
6. [6] Libby, P., Hansson, G.K., Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 116 (2015), 307–311.
7. [7] Kleemann, R., Verschuren, L., Morrison, M., Zadelaar, S., van Erk, M.J., Wielinga, P.Y., et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218 (2011), 44–52.
8. [8] Lou-Bonafonte, J.M., Arnal, C., Navarro, M.A., Osada, J., Efficacy of bioactivecompounds from extra virgin olive oil to modulate atherosclerosis development. Mol Nutr Food Res 56 (2012), 1043–1057.
9. [9] Uchida, M., Ishii, I., Inoue, C., Akisato, Y., Watanabe, K., Hosoyama, S., et al. Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet. J Atheroscler Thromb 17 (2010), 980–988.
10. [10] Gomes, I.B., Porto, M.L., Santos, M.C., Campagnaro, B.P., Gava, A.L., Meyrelles, S.S., et al. The protective effects of oral low-dose quercetin on diabetic nephropathy in hypercholesterolemic mice. Front Physiol, 6, 2015, 247.
11. [11] Reiner, M.F., Stivala, S., Camici, G.G., Beer, J.H., [The effects of Omega-3 fatty acids in clinical medicine]. Praxis (Bern 1994) 103 (2014), 329–335.
12. [12] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22 (2014), 851–857.
13. [13] Becerra-Tomás, N., Guasch-Ferré, M., Quilez, J., Merino, J., Ferré, R., Díaz-LópezA,Bulló, M., et al. Effect of functional bread rich in potassium, γ-aminobutyric acid and angiotensin-converting enzyme inhibitors on blood pressure, glucose metabolism and endothelial function: a double blind randomized crossover clinical trial. Medicine (Baltimore), 94, 2015, e1807.
14. [14] Shiby, V.K., Mishra, H.N., Fermented milks and milk products as functional foods—a review. Crit Rev Food Sci Nutr 53 (2013), 482–496.
15. [15] Prado, M.R., Blandón, L.M., Vandenberghe, L.P., Rodrigues, C., Castro, G.R., Thomaz-Soccol, V., et al. Milk kefir: composition, microbial cultures, biological activities, and related products. Front Microbiol, 6, 2015, 1177.
16. [16] Friques, A.G., Arpini, C.M., Kalil, I.C., Gava, A.L., Leal, M.A., Porto, M.L., et al. Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats. J Transl Med, 13, 2016, 390.
17. [17] Banjoko, I.O., Adeyanju, M.M., Ademuyiwa, O., Adebawo, O.O., Olalere, R.A., Kolawole, M.O., et al. Hypolipidemic effects of lactic acid bacteria fermented cereal in rats. Lipids Health Dis, 11, 2012, 170.
18. [18] Jascolka, T.L., Aguilar, E.C., Teixeira, L.G., Lages, P.C., Raimundo, I.C., Beltrão, N.R.M., et al. Kefir supplementation improves lipid profile and oxidative stress but does not reduce atherosclerotic lesion in apoE deficient mice. J Food Nutr Disord, 2, 2013, 3.
19. [19] Diniz, R.O., Garla, L.K., Schneedorf, J.M., Carvalho, J.C., Study of anti-inflammatory activity of Tibetan mushroom, a symbiotic culture of bacteria and fungi encapsulated into a polysaccharide matrix. Pharmacol Res 47 (2003), 49–52.
20. [20] Güven, A., Güven, A., Gülmez, M., The effect of kefir on the activities of GSH-Px, GST, CAT, GSH and LPO levels in carbon tetrachloride-induced mice tissues. J Vet Med B Infect Dis Vet Public Health 50 (2003), 412–416.
21. [21] Clare, D.A., Swaisgood, H.E., Bioactive milk peptides: a prospectus. J Dairy Sci 83 (2000), 1187–1195.
22. [22] Ebner, J., Aşçı-Arslan, A., Fedorova, M., Hoffmann, R., Küçükçetin, A., Pischetsrieder, M., Peptide profiling of bovine kefir reveals 236 unique peptides released from caseins during its production by starter culture or kefir grains. J Proteomics 117 (2015), 41–57.
23. [23] Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H.M., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27 (2007), 1706–1721.
24. [24] Kapourchali, F.R., Surendiran, G., Chen, L., Uitz, E., Bahadori, B., Moghadasian, M.H., Animal models of atherosclerosis. World J Clin Cases 2 (2014), 126–132.
25. [25] Zhao, Y., Pennings, M., Hildebrand, R.B., Ye, D., Calpe-Berdiel, L., Out, R., et al. Enhanced foam cell formation, atherosclerotic lesion development, and inflammation by combined deletion of ABCA1 and SR-BI in bone marrow-derived cells in LDL receptor knockout mice on western-type diet. Circ Res 107 (2010), e20–e31.
26. [26] Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J 22 (2008), 659–661.
27. [27] Tsai, J., Chen, T., Pan, B.S., Gong, S., Chung, M., Antihypertensive effect of bioactive peptides produced by protease-facilitated lactic acid fermentation of milk. Food Chem 106 (2008), 552–558.
28. [28] Tonini, C.L., Campagnaro, B.P., Louro, L.P., Pereira, T.M., Vasquez, E.C., Meyrelles, S.S., Effects of aging and hypercholesterolemia on oxidative stress and DNA damage in bone marrow mononuclear cells in apolipoprotein E-deficient mice. Int J Mol Sci 14 (2013), 3325–3342.
29. [29] Klippel, B.F., Duemke, L.B., Leal, M.A., Friques, A.G., Dantas, E.M., Dalvi, R.F., et al. Effects of kefir on the cardiac autonomic tones and baroreflex sensitivity in spontaneously hypertensive rats. Front Physiol, 7, 2016, 211.
30. [30] Dallas, D.C., Citerne, F., Tian, T., Silva, V.L., Kalanetra, K.M., Frese, S.A., et al. Peptidomic analysis reveals proteolytic activity of kefir microorganisms on bovine milk proteins. Food Chem 197 (2016), 273–284.
31. [31] Korhonen, H., Milk-derived bioactive peptides: from science to applications. J Funct Foods 1 (2009), 177–187.
32. [32] Cánovas, J.M., Rentero, P.Z., Martínez, A.M., Hernández, M.L., Alemán, J.A., Péptidos bioactivos. Clin Invest Arterioscl 23 (2011), 219–227.
33. [33] Lu, M., Wang, X., Sun, G., Qin, B., Xiao, J., Yan, S., et al. Fine structure of Tibetan kefir grains and their yeast distribution, diversity, and shift. PLoS One, 9, 2014, e101387.
34. [34] Magalhães, K.T., de Melo Pereira, G.V., Campos, C.R., Dragone, G., Schwan, R.F., Brazilian kefir: structure, microbial communities and chemical composition. Braz J Microbiol 42 (2011), 693–702.
35. [35] Kourkoutas, Y., Kandylis, P., Panas, P., Dooley, J.S., Nigam, P., Koutinas, A.A., Evaluation of freeze-dried kefir coculture as starter in feta-type cheese production. Appl Environ Microbiol 72 (2006), 6124–6135.
36. [36] Yener, A.U., Sehitoglu, M.H., Ozkan, M.T., Bekler, A., Ekin, A., Cokkalender, O., et al. Effects of kefir on ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci 19 (2015), 887–896.
37. [37] Witthuhn, R.C., Schoeman, T., Britz, T.J., Isolation and characterization of the microbial population of different South African kefir grains. Int J Dairy Technol 57 (2004), 33–37.
38. [38] Bourrie, B.C., Willing, B.P., Cotter, P.D., The microbiota and health promoting characteristics of the fermented beverage kefir. Front Microbiol, 7, 2016, 647.
39. [39] Ooi, L.G., Liong, M.T., Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 11 (2010), 2499–2522.
40. [40] Kumar, M., Nagpal, R., Kumar, R., Hemalatha, R., Verma, V., Kumar, A., et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res, 2012, 2012, 902917.
41. [41] Angelis-Pereira, M.C., Barcelos Mde, F., Sousa, M.S., Pereira Jde, A., Effects of the kefir and banana pulp and skin flours on hypercholesterolemic rats. Acta Cir Bras 28 (2013), 481–486.
42. [42] Greany, K.A., Bonorden, M.J., Hamilton-Reeves, J.M., McMullen, M.H., Wangen, K.E., Phipps, W.R., et al. Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr 62 (2008), 232–237.
43. [43] St-Onge, M.P., Farnworth, E.R., Savard, T., Chabot, D., Mafu, A., Jones, P.J., Kefir consumption does not alter plasma lipid levels or cholesterol fraction al synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]. BMC Complement Altern Med, 2, 2002, 1.
44. [44] Ostadrahimi, A., Taghizadeh, A., Mobasseri, M., Farrin, N., Payahoo, L., Beyramalipoor Gheshlaghi, Z., et al. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health 44 (2015), 228–237.
45. [45] Nakamura, T., Hirota, T., Mizushima, K., Ohki, K., Naito, Y., Yamamoto, N., et al. Milk-derived peptides, Val-Pro-Pro and Ile-Pro-Pro, attenuate atherosclerosis development in apolipoprotein e-deficient mice: a preliminary study. J Med Food 16 (2013), 396–403.
46. [46] Ait-Oufella, H., Taleb, S., Mallat, Z., Tedgui, A., Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31 (2011), 969–979.
47. [47] Meyrelles, S.S., Peotta, V.A., Pereira, T.M., Vasquez, E.C., Endothelial dysfunction in the apolipoprotein E-deficient mouse: Insights into the influence of diet, gender and aging. Lipids Health Dis, 10, 2011, 211.
48. [48] Conti, P., Shaik-Dasthagirisaeb, Y., Atherosclerosis: a chronic inflammatory disease mediated by mast cells. Cent Eur J Immunol 40 (2015), 380–386.
49. [49] Chakrabarti, S., Wu, J., Milk-derived tripeptides IPP (Ile-Pro-Pro) and VPP (Val-Pro-Pro) promote adipocyte differentiation and inhibit inflammation in 3 T3-F442 A cells. PLoS One, 10, 2015, e0117492.
50. [50] Coste, M., Rochet, V., Léonil, J., Mollé, D., Bouhallab, S., Tomé, D., Identification of C terminal peptides of bovine β-casein that enhance proliferation of rat lymphocytes. Immunol Lett 33 (1992), 41–46.
51. [51] Kudoh, Y., Matsuda, S., Igoshi, K., Oki, T., Antioxidative peptide from milk fermented with Lactobacillus delbrueckii subsp. bulgaricus IFO13953. Nippon Shokuhin Kagaku Kogaku Kaishi 48 (2001), 44–50.
52. [52] Eisele, T., Stressler, T., Kranz, B., Fischer, L., Bioactive peptides generated in an enzyme membrane reactor using Bacillus lentus alkaline peptidase. Eur Food Res Technol 236 (2013), 483–490.
53. [53] Aguilar, E.C., Leonel, A.J., Teixeira, L.G., Silva, A.R., Silva, J.F., Pelaez, J.M., et al. Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFκB activation. Nutr Metab Cardiovasc Dis 24 (2014), 606–613.
54. [54] Leite, A.M., Leite, D.C., Del Aguila, E.M., Alvares, T.S., Peixoto, R.S., Miguel, M.A., et al. Microbiological and chemical characteristics of Brazilian kefir during fermentation and storage processes. J Dairy Sci 96 (2013), 4149–4159.